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Abstract
Summary Trabecular bone score (TBS) assesses bone quality
in the lumbar spine using dual-energy X-ray absorptiometry
(DXA) scans. In postmenopausal women with osteoporosis,
denosumab significantly improved TBS independently of
bone mineral density (BMD). This practical technique may
have a role in managing patients with osteoporosis.
Introduction TBS, a gray-level texture index determined from
lumbar spine DXA scans, correlates with bone microarchitecture
and enhances assessment of vertebral fracture risk independently
of BMD. In the FREEDOM study, denosumab increased BMD
and reduced new vertebral fractures in postmenopausal women
with osteoporosis. This retrospective analysis explored the effect
of denosumab on TBS and the association between TBS and
BMD in FREEDOM.
Methods Postmenopausal women with lumbar spine or total
hip BMD T-score <−2.5 and −4.0 or higher at both sites re-
ceived placebo or denosumab 60 mg subcutaneously every
6 months. TBS indices were determined from DXA scans at
baseline and months 12, 24, and 36 in a subset of 285 women
(128 placebo, 157 denosumab) who had TBS values at base-
line and ≥1 postbaseline visit.
Results Baseline characteristics were comparable between
treatment groups; mean (SD) lumbar spine BMD T-score
was −2.79 (0.64), and mean (standard deviation [SD]) TBS
was 1.200 (0.101) overall. In the placebo group, BMD and
TBS increased by ≤0.2% or decreased from baseline at each
visit. In the denosumab group, progressive increases from
baseline at 12, 24, and 36 months were observed for BMD
(5.7, 7.8, and 9.8%) and TBS (1.4, 1.9, and 2.4%). Percentage
changes in TBS were statistically significant compared with
baseline (p < 0.001) and placebo (p ≤ 0.014). TBS was largely
unrelated to BMD, regardless of treatment, either at baseline
or for annual changes from baseline (all r2 ≤ 0.06).
Conclusions In postmenopausal women with osteoporosis,
denosumab significantly improved TBS independently of
BMD.
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Introduction
Measurement of bone mineral density (BMD) using dual-
energy X-ray absorptiometry (DXA) is the standard technique
to assess bone density and fracture risk in postmenopausal
women [1]. Decreased BMD is an established risk factor for
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hip fracture and other osteoporotic fractures [2]. However, use
of BMD lacks sensitivity for predicting vertebral fracture [3].
BMD also does not provide insight into bone microstructure
and altered bone microarchitecture, which are important fac-
tors for fragility fractures [4].
The trabecular bone score (TBS) uses two-dimensional
scans obtained during routine DXA for BMD assessment
and experimental variograms to characterize the three-
dimensional rate of gray-level amplitude variations in trabec-
ular bone [5–8]. Projection of healthy bone microstructure
onto a plane results in a large number of low-amplitude
pixel-to-pixel variations, whereas projection of osteoporotic
bone microstructure onto a plane results in a low number of
high-amplitude pixel-to-pixel variations in a given direction.
Accordingly, an elevated TBS value correlates with better
skeletal microstructure, and a lower TBS value correlates with
more disrupted and weaker skeletal microstructure [8]. The
DXA scans of vertebrae L1–L4 obtained to assess lumbar
spine BMD can also be used to generate TBS, thereby pro-
ducing complementary skeletal information from the same
examination [6]. TBS has been shown to be significantly as-
sociated with direct measurements of bone microarchitecture
and mechanical behavior [5, 8–10] and is predictive of current
[6, 11–16] and future [17–19] fragility fractures in postmeno-
pausal women with primary osteoporosis [19, 20]. TBS can
also be used to assess fracture risk in patients with specific
causes of secondary osteoporosis such as hyperparathyroid-
ism, diabetes, and glucocorticoid treatment [21, 22]. TBS in-
creases the ability of the Fracture Risk Assessment Tool
(FRAX) to categorize fracture risk, and it has been incorpo-
rated into the FRAX model as an adjustment factor [20, 23,
24]. Thus, TBS has been newly included in international
guidelines [25], providing an additional tool to identify and
improve the characterization of patients at risk for fracture and
in need of therapeutic intervention.
Denosumab is a fully human monoclonal antibody against
RANK ligand, which is a key mediator of the formation, ac-
tivation, and survival of osteoclasts [26–29]. In the 3-year
FREEDOM study of 7808 postmenopausal women with os-
teoporosis, subcutaneous administration of denosumab every
6 months was associated with significant reduction in new
vertebral and nonvertebral fractures in women with osteopo-
rosis compared with placebo [30]. A subset of women in the
FREEDOM study participated in a prospective DXA
substudy, in which the results for lumbar spine BMD were
comparable to those from the primary study [31]. The objec-
tive of this retrospective analysis was to explore the effect of
denosumab on TBS and the association between TBS and
lumbar spine BMD in FREEDOM. Although denosumab
therapy does not improve the trabecular connectivity, resorp-
tion spaces and stress risers on trabecular surfaces are filled in,
strengthening existing trabeculae. This in-filling of resorption
cavities results in slight thickening of trabeculae, at least at the
sites of active resorption when denosumab therapy starts, a
change that would be reflected in the TBS.
Materials and methods
Study design
The study design and primary endpoints of the FREEDOM
study [30] and the DXA substudy [31] were reported previ-
ously. FREEDOM was an international, multicenter, random-
ized, double-blind, placebo-controlled study that included
7808 postmenopausal women with osteoporosis. Subjects
were randomized 1:1 centrally, in a double-blinded fashion,
to receive either denosumab 60mg or placebo subcutaneously
every 6 months for 36 months. All subjects received daily
supplementation of calcium (≥1000 mg) and vitamin D
(≥400 IU).
Of the 213 study centers that participated in the
FREEDOM study, 19 centers also participated in the DXA
substudy and performed more frequent BMD assessments
and evaluations of additional skeletal sites for 441 subjects.
These subjects provided separate informed consent to partic-
ipate in the DXA substudy.
Subjects
Postmenopausal women with a BMD T-score lower than
−2.5 at the lumbar spine or total hip and −4.0 or higher at both
sites were eligible for participation in the FREEDOM study if
they were naïve to osteoporosis treatment or had received
prior bisphosphonate treatment for <3 years and not within
12 months of study entry and if they were free of other con-
ditions known to impact bonemetabolism. Aminimum of two
evaluable lumbar vertebrae in the L1–L4 region and one
evaluable hip (left or right) was required for inclusion.
Subjects with at least one severe or more than two moderate
vertebral fractures at screening were excluded.
Study assessments
Lumbar spine BMD assessments in the DXA substudy of the
FREEDOM study were performed at baseline and at 1, 6, 12,
24, and 36 months. BMD was measured by Lunar or Hologic
DXA bone densitometers, and the same machine was used for
all measurements for an individual subject. Lumbar spine
scans included L1–L4 vertebrae; prevalent or incident frac-
tured vertebrae confirmed by X-rays were excluded from the
lumbar spine analysis. DXA scans were submitted to a central
imaging vendor for analysis (Synarc Inc., San Francisco, CA,
USA) who also monitored scanner stability and cross-
calibration throughout the study, as well as the quality and
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reliability of the individual subject scans. The results of the
DXA substudy have been published [31].
This analysis retrospectively applied software (TBS
iNsight® v1.9, Medimaps, Merignac, France) to lumbar spine
DXA scans in a blinded-to-treatment manner to determine the
TBS of subjects who participated in the DXA substudy.
Lumbar spine TBS was calculated as the mean of the individ-
ual measurements for L1–L4 vertebrae, excluding those ver-
tebrae that were not included from BMD assessments because
of evidence of fracture or external artifact. However, vertebrae
excluded from BMD measurement due to osteophytes or de-
generative changes were included in the TBS analyses. Only
DXA scans from recent-generation scanners (GE Healthcare
Prodigy™, iDXA™, Hologic QDR 4500™, Discovery™,
and Horizon™) with sufficient resolution and signal-noise
ratio in the acquired scan can be analyzed by the TBS
iNsight® software. Because of the post hoc retrospective anal-
ysis nature of this study, the DXA scanners were not cross-
calibrated using a dedicated TBS fractal phantom.
Statistical analyses
The analyses included subjects with TBS and lumbar spine
BMD measurements at baseline and at least one postbaseline
visit. Missing data were not imputed. The percentage changes
from baseline in lumbar spine BMD and TBS were analyzed
using a repeated-measures model, adjusting for treatment, vis-
it, baseline value, machine type, treatment-by-visit interaction,
and baseline value-by-machine type interaction. Statistical in-
ferences on differences relative to placebo at each time point
as well as differences relative to baseline were assessed, with
no adjustment for multiplicity. The results were reported as
least-squares means and associated two-sided 95% confidence
intervals for the treatment difference at each time point. Using
the least significant change (LSC) with TBS of 5.82% identi-
fied in a previous study [17], the percentages of subjects with
TBS change ≥LSC were calculated for each time point for
each treatment group. Pearson correlation coefficients were
calculated for the relationships between lumbar spine BMD
and TBS at baseline and for the percentage change from
baseline.
Results
Of the 441 postmenopausal women with osteoporosis
who part icipated in the DXA substudy of the
FREEDOM study, 285 (128 placebo, 157 denosumab)
had measurable TBS data at baseline and at least one
postbaseline visit and were included in this analysis.
Among these subjects, baseline characteristics were
comparable between the placebo and denosumab groups
(Table 1). Mean (SD) age at baseline was 72.5 years
(5.0). Mean (SD) lumbar spine BMD T-score at baseline
was −2.79 (0.64), and mean (SD) TBS at baseline was
1.200 (0.101). Mean values at baseline for BMD and
TBS were lower for Hologic than Lunar bone densitom-
eters in each treatment group. Except for fewer preva-
lent vertebral fractures (6.7 vs 23.6% in the entire
FREEDOM cohort), the baseline characteristics of pa-
tients in the DXA substudy did not differ from those
described in FREEDOM [30].
In the denosumab group, progressive increases from base-
line at 12, 24, and 36 months were observed for lumbar spine
BMD (mean increases of 5.7, 7.8, and 9.8%, respectively) and
TBS (mean increases of 1.4, 1.9, and 2.4%, respectively) (Fig.
1). The changes in both BMD and TBS in the denosumab
group were statistically significant compared with baseline
(all p < 0.001) and placebo (all p ≤ 0.014).
More subjects in the denosumab group than in the placebo
group had TBS gains of 5.82% or greater at 12 months (15 vs
11%; p = 0.271), 24 months (21 vs 9%; p = 0.012), and
36 months (20 vs 6%; p = 0.001).
BMD explained a very small fraction of the variability in
TBS at baseline (r2 = 0.06; Fig. 2). TBS change was also
largely unrelated to BMD change at month 12 (r2 < 0.01 for
placebo and r2 = 0.03 for denosumab), month 24 (r2 < 0.01 for
placebo and r2 = 0.02 for denosumab), and month 36
(r2 = 0.03 for placebo and r2 = 0.05 for denosumab; Fig. 3).
Table 1 Baseline characteristics
Placebo
(n = 128)
Denosumab
(n = 157)
Age (years), mean ± SD 72.3 ± 5.4 72.8 ± 4.7
Body mass index (kg/m2),
mean ± SD
25.1 ± 4.3 25.1 ± 4.1
Race, n (%)
White or Caucasian 108 (84.4) 137 (87.3)
Hispanic or Latino 18 (14.1) 19 (12.1)
Other 2 (1.6) 1 (0.6)
Prevalent vertebral fracture, n (%) 7 (5.5) 12 (7.6)
Lumbar spine BMD, mean ± SD
Either machine, T-score −2.83 ± 0.56 −2.75 ± 0.69
Hologica (g/cm2) 0.74 ± 0.06 0.74 ± 0.07
Lunara (g/cm2) 0.83 ± 0.06 0.86 ± 0.09
TBS, mean ± SD
Either machine 1.200 ± 0.099 1.200 ± 0.103
Hologica 1.193 ± 0.099 1.194 ± 0.103
Lunara 1.229 ± 0.093 1.220 ± 0.102
BMD bone mineral density, SD standard deviation, TBS trabecular bone
score
a Number of subjects: Hologic: 103 placebo, 121 denosumab, and 224
total; Lunar: 25 placebo, 36 denosumab, and 61 total
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Discussion
In this retrospective analysis of a subset of postmenopausal
women with osteoporosis in the FREEDOM study, significant
and progressive increases from baseline at 12, 24, and
36 months were observed for both BMD and TBS in the
denosumab group.
A previous analysis of 92 women from the FREEDOM
study reported that denosumab reduced bone turnover com-
pared with placebo when assessed by bone histomorphometry
of iliac crest bone biopsies and analysis of bone turnover
markers [32]. Reduced bone turnover and increased BMD
following denosumab treatment have been associated with
improvement in trabecular and cortical bone at the spine
[33] and a significant reduction (68%) in new vertebral frac-
tures [30].
TBS derived from existing DXA scans of the lumbar spine
provides information about bone architecture and fracture risk
[13, 17], which could assist physicians in identifying patients
at risk of fracture [22, 25]. TBS has also been shown to reflect
therapeutic responses to osteoporosis treatments [34-36] and
could assist in the monitoring of the effectiveness of a therapy.
Indeed, pharmacologic intervention studies suggest that TBS
improves with treatments that increase BMD, but the magni-
tude of change is less marked than BMD. The change in TBS
also appears to be influenced by the type of therapy for oste-
oporosis. Previous studies have reported greater improvement
in TBSwith an anabolic therapy such as teriparatide compared
with a bisphosphonate [37, 38]. In this study, denosumab was
associated with significantly greater improvement in TBS
than placebo at each of the annual assessments. Our findings
are consistent with results of an open-label study that investi-
gated different treatments, including denosumab [37]. The
results for TBS in this study support its usefulness as an addi-
tional tool in routine clinical practice to assess bone
microarchitecture noninvasively.
The lack of a significant correlation between TBS and
BMD in our study is important for several reasons. Firstly, it
supports the principle that TBS provides a measure of bone
not captured by densitometric techniques; secondly, it pro-
vides complementary information that has proved useful and
practical for patient identification [6, 17]; and lastly, it may
allow for an improved assessment of differences in responses
to diverse therapies for osteoporosis.
A limitation of this analysis was that it included only a
small subset of the total FREEDOM population, precluding
an assessment of the relationship between changes in TBS and
fracture risk reductions. Mean percentage changes from base-
line in lumbar spine BMD at 12, 24, and 36 months in this
analysis were comparable to those reported previously in the
primary analysis of the FREEDOM study [30] and in the
Fig. 1 Percentage change from baseline by visit for lumbar spine BMD
(a) and TBS (b) by treatment group. Based on a repeated-measures model
adjusting for treatment, visit, baseline value, machine type, treatment-by-
visit interaction, and baseline value-by-machine type interaction. Data are
presented as least-squares mean and 95% CI. *p ≤ 0.014 compared with
placebo; †p < 0.001 compared with baseline. BMD bone mineral density,
CI confidence interval, Q6M every 6 months, TBS trabecular bone score
Fig. 2 Relationship between lumbar spine BMD and TBS at baseline.
Pearson correlation: r2 = 0.06. BMD bonemineral density, TBS trabecular
bone score
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BMD analysis in the FREEDOM DXA substudy [31].
Because TBS provides distinct information from BMD, it is
possible that the other womenwho participated in FREEDOM
could have TBS responses that differed from those observed
in this subpopulation. Whereas differences in baseline BMD
were observed by machine type in this study, the same ma-
chine was used for all measurements for an individual subject,
and the analyses were adjusted for machine type and other
baseline values. Whereas most subjects had improved BMD
with denosumab treatment, approximately one in three sub-
jects did not have improvement in TBS. Changes in BMD
have been reported to reflect a large portion of the efficacy
of denosumab, with a stronger association for nonvertebral
fractures than vertebral fractures [39]. It is possible that the
combination of BMD and TBS provides a more complete
assessment of fracture risk than either approach alone, but
our small study could not determine whether changes in
TBS accounted for any of the remaining effects of treatment
on fracture risk.
In conclusion, these analyses showed that denosumab treat-
ment in postmenopausal women results in significant and pro-
gressive increases in TBS compared with placebo and base-
line over 3 years. TBS is largely unrelated to BMD, either at
baseline or for changes from baseline during denosumab treat-
ment, supporting the concept that TBS provides distinct infor-
mation, independent of BMD. These results, coupled with the
previous observations that TBS correlates with fracture risk,
suggest that this practical technique may have a role in man-
aging patients with osteoporosis. These results provide impe-
tus for additional investigation of the relationship between
changes in TBS and changes in fracture risk during treatment,
which if established, could support the use of TBS to assist in
selecting the most suitable treatment for an individual patient.
Acknowledgments This work was supported by Amgen Inc. Jonathan
Latham (PharmaScribe, LLC, on behalf of Amgen Inc.) and Mandy
Suggitt (Amgen Inc.) provided medical writing support.
Compliance with ethical standards
Ethical approval The study complied with the principles of the
Declaration of Helsinki. Institutional review boards and ethics commit-
tees approved the protocol and consent process. All procedures per-
formed in studies involving human participants were in accordance with
the ethical standards of the institutional and/or national research commit-
tee and with the 1964 Helsinki Declaration and its later amendments or
comparable ethical standards.
Informed consent Subjects provided informed consent to participate.
Conflicts of interest MRMcClung: consultancy—Amgen Inc.,Merck,
and Radius; and lecture fees—Amgen Inc. and Merck.
K Lippuner: consultancy and principal investigator—Amgen Inc. and
MSD.
ML Brandi: research grants—Amgen Inc.
JR Zanchetta: lecture fees—Amgen Inc. and GlaxoSmithKline.
HG Bone: research grants—Amgen Inc. and Merck; consulting
fees/honoraria—Amgen Inc., Merck, Radius, and Mission; lecture
fees—Amgen Inc.; travel support—Amgen Inc.; fees for review activi-
ties—Amgen Inc.; and development of educational presentations—
Vindico.
R Chapurlat: research grants, travel support, consultancy, and lecture
fees—Amgen Inc.
D Hans: received fees per scan from Amgen to make central calcula-
tion of TBS on publication; board membership, stock/stock options, and
employment—Medimaps Group; and co-owner of the TBS patent.
AWang: employee and stock/stock options—Amgen Inc.
C Zapalowski: employee—Radius Health; prior employment—
Amgen Inc.; and stock/stock options—Amgen Inc. and Radius Health.
C Libanati: employee—UCB Pharma; and stock/stock options—
UCB Pharma and Amgen Inc.
Fig. 3 Relationship between lumbar spine BMD and TBS percentage
change from baseline at month 36 by (a) placebo and (b) denosumab.
Pearson correlation: r2 = 0.03 (placebo); r2 = 0.05 (denosumab). BMD
bone mineral density, TBS trabecular bone score
Osteoporos Int
References
1. (1994) Assessment of fracture risk and its application to screening
for postmenopausal osteoporosis. Report of a WHO Study Group.
World Health Organ Tech Rep Ser 843:1–129
2. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P,
Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ,
Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A,
Tenenhouse A (2005) Predictive value of BMD for hip and other
fractures. J Bone Miner Res 20:1185–1194
3. Hordon LD, Raisi M, Aaron JE, Paxton SK, Beneton M, Kanis JA
(2000) Trabecular architecture in women and men of similar bone
mass with and without vertebral fracture: I. Two-dimensional his-
tology. Bone 27:271–276
4. Majumdar S (1998) A review of magnetic resonance (MR) imaging
of trabecular bone micro-architecture: contribution to the prediction
of biomechanical properties and fracture prevalence. Technol
Health Care 6:321–327
5. Pothuaud L, Carceller P, Hans D (2008) Correlations between grey-
level variations in 2D projection images (TBS) and 3D
microarchitecture: applications in the study of human trabecular
bone microarchitecture. Bone 42:775–787
6. Pothuaud L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D
(2009) Evaluation of the potential use of trabecular bone score to
complement bone mineral density in the diagnosis of osteoporosis:
a preliminary spine BMD-matched, case-control study. J Clin
Densitom 12:170–176
7. Winzenrieth R, Michelet F, Hans D (2013) Three-dimensional (3D)
microarchitecture correlations with 2D projection image gray-level
variations assessed by trabecular bone score using high-resolution
computed tomographic acquisitions: effects of resolution and noise.
J Clin Densitom 16:287–296
8. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg
MA (2011) Correlations between trabecular bone score, measured
using anteroposterior dual-energy X-ray absorptiometry acquisi-
tion, and 3-dimensional parameters of bone microarchitecture: an
experimental study on human cadaver vertebrae. J Clin Densitom
14:302–312
9. Roux JP, Wegrzyn J, Boutroy S, Bouxsein ML, Hans D, Chapurlat
R (2013) The predictive value of trabecular bone score (TBS) on
whole lumbar vertebrae mechanics: an ex vivo study. Osteoporos
Int 24:2455–2460
10. Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann
P, Hans D, Muschitz GK, Fahrleitner-Pammer A, Resch H (2015)
TBS reflects trabecular microarchitecture in premenopausal women
and men with idiopathic osteoporosis and low-traumatic fractures.
Bone 79:259–266
11. Nassar K, Paternotte S, Kolta S, Fechtenbaum J, Roux C, Briot K
(2014) Added value of trabecular bone score over bone mineral
density for identification of vertebral fractures in patients with areal
bone mineral density in the non-osteoporotic range. Osteoporos Int
25:243–249
12. Del Rio LM, Winzenrieth R, Cormier C, Di Gregorio S (2013) Is
bone microarchitecture status of the lumbar spine assessed by TBS
related to femoral neck fracture? A Spanish case-control study.
Osteoporos Int 24:991–998
13. Winzenrieth R, Dufour R, Pothuaud L, Hans D (2010) A retrospec-
tive case-control study assessing the role of trabecular bone score in
postmenopausal Caucasian women with osteopenia: analyzing the
odds of vertebral fracture. Calcif Tissue Int 86:104–109
14. Rabier B, Héraud A, Grand-Lenoir C, Winzenrieth R, Hans D
(2010) A multicentre, retrospective case-control study assessing
the role of trabecular bone score (TBS) in menopausal Caucasian
women with low areal bone mineral density (BMDa): analysing the
odds of vertebral fracture. Bone 46:176–181
15. Touvier J, Winzenrieth R, Johansson H, Roux JP, Chaintreuil J,
Toumi H, Jennane R, Hans D, Lespessailles E (2015) Fracture
discrimination by combined bone mineral density (BMD) and
microarchitectural texture analysis. Calcif Tissue Int 96:274–283
16. Leib E, Winzenrieth R, Lamy O, Hans D (2014) Comparing bone
microarchitecture by trabecular bone score (TBS) in Caucasian
American women with and without osteoporotic fractures. Calcif
Tissue Int 95:201–208
17. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone
microarchitecture assessed by TBS predicts osteoporotic fractures
independent of bone density: the Manitoba study. J Bone Miner
Res 26:2762–2769
18. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth
R, Chapurlat R (2013) Trabecular bone score improves fracture risk
prediction in non-osteoporotic women: the OFELY study.
Osteoporos Int 24:77–85
19. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N,
McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone
score: a noninvasive analytical method based upon the DXA image.
J Bone Miner Res 29:518–530
20. McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D,
Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R,
Elders PJ, Fujita Y, Glüer CC, Goltzman D, Iki M, Karlsson M,
Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O,
Leung J, Lippuner K, Ljunggren O, Lorentzon M, Mellström D,
Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren
B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA (2016) A meta-
analysis of trabecular bone score in fracture risk prediction and its
relationship to FRAX. J Bone Miner Res 31:940–948
21. Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP,
Caudarella R (2014) Utility of the trabecular bone score (TBS) in
secondary osteoporosis. Endocrine 47:435–448
22. Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML,
Cooper C, Kendler D, Lamy O, Laslop A, Camargos BM,
Reginster JY, Rizzoli R, Kanis JA (2015) Trabecular bone score
(TBS) as a new complementary approach for osteoporosis evalua-
tion in clinical practice. Bone 78:216–224
23. Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey
EV, Hans D (2014) Lumbar spine texture enhances 10-year fracture
probability assessment. Osteoporos Int 25:2271–2277
24. McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D,
Johansson H, Kanis JA (2015) Adjusting fracture probability by
trabecular bone score. Calcif Tissue Int 96:500–509
25. Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie
WD (2015) Fracture risk prediction by non-BMD DXA measures:
the 2015 ISCD Official Positions Part 2: trabecular bone score. J
Clin Densitom 18:309–330
26. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T,
Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J,
Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S,
Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ
(1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell 93:165–176
27. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M,
Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N,
Suda T (1998) Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602
28. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A,
Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ,
Polverino AJ (2000) Osteoprotegerin ligand modulates murine os-
teoclast survival in vitro and in vivo. Am J Pathol 157:435–448
29. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y,
Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000)
Osteoprotegerin produced by osteoblasts is an important regulator
Osteoporos Int
in osteoclast development and function. Endocrinology 141:3478–
3484
30. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R,
Reid IR, Delmas P, ZoogHB, AustinM,Wang A, Kutilek S, Adami
S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009)
Denosumab for prevention of fractures in postmenopausal women
with osteoporosis. N Engl J Med 361:756–765
31. Bolognese MA, Teglbjærg CS, Zanchetta JR, Lippuner K,
McClung MR, Brandi ML, Høiseth A, Lakatos P, Moffett AH,
Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly
increases DXA BMD at both trabecular and cortical sites: results
from the FREEDOM study. J Clin Densitom 16:147–153
32. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A,
Valter I, Maasalu K, BologneseMA,Woodson G, Bone H, Ding B,
Wagman RB, San Martin J, Ominsky MS, Dempster DW (2010)
Effects of denosumab on bone histomorphometry: the FREEDOM
and STAND studies. J Bone Miner Res 25:2256–2265
33. Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler
D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R,
Kopperdahl DL, Engelke K, Fuerst T, Radcliffe HS, Libanati C
(2014) Femoral and vertebral strength improvements in postmeno-
pausal women with osteoporosis treated with denosumab. J Bone
Miner Res 29:158–165
34. Hans D, Krieg M, Lamy O, Felsenberg D (2012) Beneficial effects
of strontium ranelate compared to alendronate on trabecular bone
score in post menopausal osteoporotic women. A 2-year study (ab-
stract). Osteoporos Int 23(Suppl 2):S266–S267
35. Krieg MA, Aubry-Rozier B, Hans D, Leslie WD, Manitoba Bone
Density Program (2013) Effects of anti-resorptive agents on trabec-
ular bone score (TBS) in older women. Osteoporos Int 24:1073–
1078
36. Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D,
Lippuner K (2013) Effects of zoledronate versus placebo on spine
bone mineral density and microarchitecture assessed by the trabec-
ular bone score in postmenopausal women with osteoporosis: a
three-year study. J Bone Miner Res 28:449–454
37. Di Gregorio S, Del Rio L, Rodriguez-Tolra J, Bonel E, García M,
Winzenrieth R (2015) Comparison between different bone treat-
ments on areal bone mineral density (aBMD) and bone
microarchitectural texture as assessed by the trabecular bone score
(TBS). Bone 75:138–143
38. Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K
(2014) Comparative effects of teriparatide and ibandronate on spine
bone mineral density (BMD) and microarchitecture (TBS) in post-
menopausal women with osteoporosis: a 2-year open-label study.
Osteoporos Int 25:1945–1951
39. AustinM, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC,
Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A,
Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris
ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR,
FREEDOM Trial (2012) Relationship between bone mineral den-
sity changes with denosumab treatment and risk reduction for ver-
tebral and nonvertebral fractures. J Bone Miner Res 27:687–693
Osteoporos Int
